GlassScriptPhysician profile
Sultan A Hayat
NPI 1548248453
$6,654.49
in general payments reported to CMS, 2019-2025
28 companies · $244 in 2025
The $244 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,647 · 2020: $562 · 2021: $412 · 2022: $1,168 · 2023: $1,261 · 2024: $1,359 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,864.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,031.86 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $995.00 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $979.93 | 2019-2025 | |
| Pfizer INC. | $644.77 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $476.47 | 2019-2024 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $299.75 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $278.34 | 2021-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $275.16 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $274.56 | 2019-2024 | Watchman Access System, Watchman, Bodyguardian |
| Astrazeneca Pharmaceuticals LP | $174.60 | 2019-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $151.25 | 2019-2024 | |
| Amarin Pharma, INC. | $136.25 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $123.17 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $93.24 | 2023-2024 | Inpefa |
| Gilead Sciences, INC. | $89.84 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $84.10 | 2022-2025 | Assure Wcd |
| Irhythm Technologies, INC. | $81.83 | 2024 | Zio Xt Patch, Zio Monitor |
| Regeneron Healthcare Solutions, INC. | $75.74 | 2019 | |
| Abiomed | $64.86 | 2024 | Impella |
| Abbott Laboratories | $49.09 | 2022-2023 | Jot Dx |
| Novo Nordisk INC | $46.86 | 2019-2024 | Rybelsus, Ozempic |
| Alnylam Pharmaceuticals INC. | $42.84 | 2022-2025 | Amvuttra |
| Medtronic, INC. | $40.92 | 2021-2023 | Linq II |
| Esperion Therapeutics, INC. | $38.27 | 2024 | Nexletol |
| Edwards Lifesciences Corporation | $33.18 | 2019-2022 | |
| Braemar Manufacturing, LLC | $30.48 | 2019 | |
| Covidien LP | $23.98 | 2019 | |
| Scpharmaceuticals INC. | $18.15 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sultan Hayat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.